(EN) A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of Saruparib (AZD5305) in Combination With Physician's Choice New Hormonal Agents in Patients With HRRm and Non-HRRm Metastatic Castration-Sensitive Prostate Cancer
EvoPAR-Prostate01
NCT06120491
 Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
|
Rodrigo Skowronski
514-934-1934 poste 36275
|
(EN) A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 Versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge
rechARge
NCT06764485
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
|
(EN) Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging
PROSTEP-002
NCT04655365
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Rodrigo Skowronski
514-934-1934 poste 36275
|
(EN) [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer
ACCEL
NCT06229366
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
|
Anna Perez
514-934-1934 poste 34732
|
(EN) Detection and Monitoring of Metastasis by 18F-DCFPyL PET/CT in Subjects Starting Enzalutamide for Untreated Castration Resistant Prostate Cancer and Negative Conventional Imaging
PROSTEP-002
NCT04655365
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
L'HOTEL-DIEU DE QUEBEC ET CRCEO
|
|
Marilyn Savard
418-525-4444 poste 20414
|
(EN) A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC)
MK-5684-01A Substudy
NCT06353386
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Marilyn Savard
418-525-4444 poste 67703
|
(EN) [Ac-225]-PSMA-62 Phase I/II Clinical Trial to Characterize Efficacy, Safety, Tolerability, and Dosimetry in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer
ACCEL
NCT06229366
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Carole Plante
418-525-4444 poste 15050
|
(EN) An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of AZD5305 Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer
ASCERTAIN
NCT05938270
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Marilyn Savard
418-525-4444 poste 67703
|
(EN) Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation
PREDICT-RT*
NCT04513717
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Josée Allard
418-525-4444 poste 16730
|
(EN) A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
MK-5684-003
NCT06136624
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
|
Marilyn Savard
418-525-4444 poste 67703
|
Groupe d'étude en oncologie du Québec